Tyra Biosciences initiated with a Buy at Guggenheim

Guggenheim last night initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $54 price target The firm says the company “has the right drug” to test three clinical hypotheses across three disparate patient populations, “where success in any one could generate significant upside.” The company’s dabogratinib “could find its home at lower doses in multiple diseases,” the analyst tells investors in a research note.